<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009875</url>
  </required_header>
  <id_info>
    <org_study_id>SOL-SYNBIOTIC-2021</org_study_id>
    <nct_id>NCT05009875</nct_id>
  </id_info>
  <brief_title>Food Trial Evaluating the Efficacy of SBD111 Versus Placebo for the Clinical Dietary Management of the Metabolic Processes of Osteopenia</brief_title>
  <official_title>Food Trial Evaluating the Efficacy of SBD111 Versus Placebo for the Clinical Dietary Management of the Metabolic Processes of Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solarea Bio, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solarea Bio, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to determine if the SYNBIOTIC (prebiotic and probiotic), provided&#xD;
      twice daily (capsule) will help support skeletal health in otherwise healthy postmenopausal&#xD;
      women in the early years postmenopause (1-6 years post last menstruation) over a 12-month&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine Bone Mineral Density (BMD) from baseline to 52 weeks</measure>
    <time_frame>Change in Bone Mineral Density (BMD) from baseline to 52 weeks</time_frame>
    <description>Change in Bone Mineral Density (BMD) at lumbar spine following an administration period of 52 weeks and measured by DXA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>SBD111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Food SBD111</intervention_name>
    <description>One capsule administered twice daily with morning and evening meals for 52 weeks</description>
    <arm_group_label>SBD111</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule administered twice daily with morning and evening meals for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Stated availability throughout entire study period (12 months) and willingness to&#xD;
             fulfill all details of the protocol&#xD;
&#xD;
          -  In early postmenopause (at least 1 year but a maximum of 6 years since the last&#xD;
             menstruation)&#xD;
&#xD;
          -  At least 6-months since the last intake of hormone replacement therapy&#xD;
&#xD;
          -  Dual energy X-ray absorptiometry (DXA)-derived Bone Mineral Density (BMD) T-score of&#xD;
             less than -2.49 at the lumbar spine (L1-L4), femoral neck, and total hip but no site&#xD;
             with BMD ≤ -2.5&#xD;
&#xD;
          -  Body Mass Index between 18.5 and 32.5 kg/m2&#xD;
&#xD;
          -  Normal levels of serum calcium (&lt;11mg/dL)&#xD;
&#xD;
          -  Normal cardiovascular parameters (systolic blood pressure ≤ 155 mm Hg, diastolic blood&#xD;
             pressure ≤ 95 mm Hg) healthy and medication controlled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any of the following criteria will exclude the participant from&#xD;
             participating in the study:&#xD;
&#xD;
          -  History of other bone disorders (eg. Paget's disease, or osteomalacia, osteogenesis&#xD;
             imperfecta, osteopetrosis, etc.)&#xD;
&#xD;
          -  History of cancer other than skin cancer, autoimmune disorders (rheumatoid arthritis,&#xD;
             hashimoto's, graves' disease, ect) type 2 diabetes, gastrointestinal disorders&#xD;
             (ulcerative colitis, Crohn's disease, inflammatory bowel disease, irritable bowel&#xD;
             syndrome), kidney disease or dysfunction or any other medical condition that could&#xD;
             interfere with the conduct of the study.&#xD;
&#xD;
          -  History of chronic antibiotic use&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  History of partial colectomy&#xD;
&#xD;
          -  Women with spine abnormalities that would prohibit assessment of BMD&#xD;
&#xD;
          -  Women who have undergone any joint replacement (hip, knee, etc.)&#xD;
&#xD;
          -  Women who have undergone a partial hysterectomy&#xD;
&#xD;
          -  Women with untreated hyperparathyroidism&#xD;
&#xD;
          -  Women previously treated with calcitonin, estrogens, estrogen derivatives, selective&#xD;
             estrogen receptor modulators (SERMs), tibolone, progestins, anabolic steroids, or&#xD;
             daily glucocorticoids in the past 6 months&#xD;
&#xD;
          -  Women treated with bisphosphonates or strontium in the past 5 years&#xD;
&#xD;
          -  Women previously treated with PTH, PTH analogs, gallium nitrate, romosozumab or&#xD;
             denosumab&#xD;
&#xD;
          -  Per-oral use of corticosteroids&#xD;
&#xD;
          -  Smoking or use of nicotine products within the past 6-months&#xD;
&#xD;
          -  Any disease, that by the investigator's judgement, could interfere with the intestinal&#xD;
             barrier function&#xD;
&#xD;
          -  Participation in other bone, diet, autoimmune, or gastrointestinal related clinical&#xD;
             trials in the last 6 months&#xD;
&#xD;
          -  Desire and/or plans on changing current diet and/or exercise regime during the&#xD;
             participation of this trial&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Consumption of dietary supplements (probiotics, prebiotics) in the month prior to or&#xD;
             during study&#xD;
&#xD;
          -  If participant is willing to stop taking these for 1-month, they can be enrolled after&#xD;
             a 1-month washout period&#xD;
&#xD;
          -  Consumption of antibiotics in the past 2 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Schott, PhD</last_name>
    <phone>585-704-8069</phone>
    <email>eschott@solareabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evidence Sciences</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Steels, PhD</last_name>
      <phone>61-431-003-929</phone>
      <email>drbeth@evidencesciences.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

